Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10781451 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
US9018368 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
US9243245 | SAREPTA THERAPS INC | Means and methods for counteracting muscle disorders |
Oct, 2028
(5 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE47751 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
USRE48468 | SAREPTA THERAPS INC | Means and methods for counteracting muscle disorders |
Oct, 2028
(5 years from now) | |
USRE47769 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Feb, 2029
(6 years from now) | |
US10337003 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(11 years from now) | |
US10364431 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(11 years from now) | |
US9506058 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 19, 2023 |
Market Authorisation Date: 19 September, 2016
Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by inducing skipping of exon 51; Treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by correcting a defective gene for dystrophin; Treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by restoring or increasing functional dystrophin protein production; Treatment of dmd in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Increasing production of functional dystrophin protein in dmd patients having a mutation of the dmd gene that is amenable to exon 51 skipping
Dosage: SOLUTION;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic